Parallel search across PubMed, Perplexity, and your knowledge base. Searches all sources simultaneously and synthesizes findings with citations. Faster evidence gathering for clinical questions.
All sources at once. This skill searches PubMed, web, and your RAG knowledge base in parallel, then synthesizes the findings into a single coherent summary with citations.
| Source | What It Searches | Output |
|---|---|---|
| PubMed | Academic literature, trials, reviews | PMIDs, abstracts, citations |
| Perplexity | Web, recent news, guidelines | Summaries with sources |
| RAG (AstraDB) | Your curated knowledge base | Guideline excerpts, textbook refs |
| Approach | Sources | Time | Depth |
|---|---|---|---|
| Sequential search | One at a time | 5+ min | Deeper but slow |
| Parallel search |
| All at once |
| 30-60 sec |
| Fast overview |
| Manual search | You do it | 20+ min | Variable |
Use this skill when you say:
"Parallel search: SGLT2 inhibitors in HFpEF"
"Find all evidence on GLP-1 and cardiovascular outcomes"
"What does literature say about statin discontinuation?"
# Basic search
python scripts/parallel_search.py --query "SGLT2 inhibitors heart failure"
# Specify sources
python scripts/parallel_search.py --query "GLP-1 cardiovascular" --sources pubmed,perplexity
# Save output
python scripts/parallel_search.py --query "CAC scoring" --output ~/research/
# Literature Search: SGLT2 Inhibitors in HFpEF
**Query:** SGLT2 inhibitors heart failure preserved ejection fraction
**Searched:** 2025-01-01 09:30:45
**Sources:** PubMed, Perplexity, RAG
---
## SYNTHESIS
SGLT2 inhibitors have demonstrated significant benefit in HFpEF based on
EMPEROR-Preserved and DELIVER trials. Key findings:
1. **EMPEROR-Preserved (PMID: 34449189)**: Empagliflozin reduced composite
endpoint of CV death/HHF by 21% (HR 0.79, 95% CI 0.69-0.90)
2. **DELIVER (PMID: 36027570)**: Dapagliflozin showed 18% reduction in
worsening HF/CV death (HR 0.82, 95% CI 0.73-0.92)
3. Current guidelines (ACC/AHA 2022) recommend SGLT2i as Class 2a for HFpEF.
---
## PUBMED RESULTS (5 most relevant)
| # | Title | PMID | Year | Type |
|---|-------|------|------|------|
| 1 | Empagliflozin in HFpEF | 34449189 | 2021 | RCT |
| 2 | Dapagliflozin in HFpEF | 36027570 | 2022 | RCT |
| 3 | Meta-analysis SGLT2i HF | 37654321 | 2023 | MA |
| 4 | Real-world SGLT2i outcomes | 38765432 | 2024 | Obs |
| 5 | SGLT2i mechanism review | 39876543 | 2024 | Rev |
---
## WEB RESULTS (Perplexity)
- **ACC 2024 Update**: New data on SGLT2i in cardiorenal syndrome
- **ESC Guidelines 2023**: Updated recommendations for SGLT2i
- **Clinical Practice**: Real-world prescribing patterns
---
## RAG RESULTS (Your Knowledge Base)
- **Braunwald Ch. 27**: Heart failure classification and treatment
- **ACC/AHA HF Guidelines**: Class recommendations for SGLT2i
- **ESC HF Guidelines**: European perspective on SGLT2i use
---
## EVIDENCE QUALITY
| Source | Strength | Notes |
|--------|----------|-------|
| EMPEROR-Preserved | High | Large RCT, well-conducted |
| DELIVER | High | Large RCT, confirmatory |
| Meta-analyses | High | Consistent findings |
| Real-world | Moderate | Observational limitations |
---
## KEY CITATIONS
1. Anker SD, et al. N Engl J Med. 2021;385:1451-1461. (PMID: 34449189)
2. Solomon SD, et al. N Engl J Med. 2022;387:1089-1098. (PMID: 36027570)
3. Vaduganathan M, et al. Lancet. 2022;400:757-767. (Meta-analysis)
---
## GAPS & CONSIDERATIONS
- Limited data in specific HFpEF phenotypes
- Long-term safety data still accumulating
- Indian-specific data limited (consider local studies)
User Query
│
├──────────────────┬──────────────────┐
│ │ │
▼ ▼ ▼
[PubMed Agent] [Perplexity Agent] [RAG Agent]
│ │ │
▼ ▼ ▼
PMIDs & Web sources Guideline
Abstracts & summaries excerpts
│ │ │
└──────────────────┴──────────────────┘
│
▼
[Synthesis Agent]
│
▼
Unified Report with
Citations & Evidence
quick-topic-researcher - Quick overviewdeep-researcher - Comprehensive reviewyoutube-script-master - Evidence for scriptscardiology-editorial - Literature for editorials# Core
anthropic>=0.18.0
python-dotenv>=1.0.0
rich>=13.0.0
# Already have these via your setup
# PubMed MCP - configured in .mcp.json
# Perplexity - via OpenRouter or MCP
| Key | Purpose | Status |
|---|---|---|
| ANTHROPIC_API_KEY | Synthesis | Already have |
| NCBI_API_KEY | PubMed (via MCP) | Already have |
| PERPLEXITY_API_KEY | Web search | Already have |
When user asks for literature/evidence:
Extract:
# PubMed (via MCP)
pubmed_search_articles(queryTerm="SGLT2 inhibitors heart failure", maxResults=10)
# Perplexity (via MCP or API)
perplexity_ask(messages=[{"role": "user", "content": "Latest evidence on SGLT2 inhibitors in heart failure 2024"}])
# RAG (if available)
# Query AstraDB for relevant guidelines
Combine findings from all sources into:
Structured report with:
The skill recognizes PICO format:
| Component | Example | How It's Used |
|---|---|---|
| Patient | "elderly patients with HFpEF" | Filters PubMed |
| Intervention | "SGLT2 inhibitors" | Primary search term |
| Comparison | "vs placebo" | Narrows to RCTs |
| Outcome | "mortality" | Focuses results |
# Basic clinical question
"SGLT2 inhibitors in heart failure"
# PICO format
"In elderly patients with HFpEF, do SGLT2 inhibitors reduce mortality compared to placebo?"
# Specific trial
"What are the key findings from EMPEROR-Preserved?"
# Guideline-focused
"Current ACC/AHA recommendations for SGLT2i in heart failure"
# Comparative
"SGLT2i vs GLP-1 for cardiovascular outcomes in diabetes"
This skill gives you evidence from multiple sources in under a minute - perfect for content preparation and quick clinical questions.